A Medical Safety Officer is a key professional responsible for overseeing the comprehensive safety monitoring of therapeutic products throughout their entire lifecycle. Their primary focus is to collect, evaluate, and interpret safety data from multiple sources, such as clinical trials, post-marketing surveillance, healthcare providers, and scientific literature. By identifying and assessing adverse events, they ensure that potential risks are recognized early and managed effectively to protect patient health. These officers collaborate closely with cross-functional teams, including medical affairs, regulatory, and quality assurance, to update risk-benefit assessments and develop appropriate safety communications. Their work ensures ongoing compliance with global regulatory standards and supports the safe use of products worldwide.
Medical Safety Officers develop and maintain risk management strategies, including the preparation of comprehensive safety documents like Periodic Safety Update Reports (PSURs) and Risk Management Plans (RMPs). They play an integral role in supporting regulatory submissions and responding to inquiries during audits and inspections. Training and educating internal teams on pharmacovigilance processes and adverse event reporting are also important responsibilities, fostering a culture of safety and vigilance. Staying current with changing regulations, guidelines, and industry best practices enables them to continuously improve safety monitoring systems. Through their diligent oversight and proactive approach, Medical Safety Officers contribute significantly to patient safety and the ongoing evaluation of therapeutic product safety profiles.
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Antibody-proteases as translational tools of the next-step generation to be applied for biopharmacy-related and precision medical practice
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Storage stability and solution binding affinity of an fc-fusion mimetic
Hanieh Khalili, University of East London, United Kingdom
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia